No Data
No Data
Beijing Tiantan Biological Products Corporation 2024 interim performance report announcement.
Express News | Tiantan Biological Products Prelim H1 Net Profit up 28.1% Y/Y
Director and General Manager of Beijing Tiantan Biological Products Corporation (600161.SH), Fu Daoxing, has resigned.
Beijing Tiantan Biological Products Corporation (600161.SH) announced that the Board of Directors received a written resignation from Mr. Fu Daoxing, the director, general manager, and legal representative of the company, due to having reached the statutory retirement age, and has proposed to resign from the above positions to the Board of Directors.
Beijing Tiantan Biological Products Corporation (600161.SH) will distribute 1.5 yuan per share with a 10-for-2 stock conversion ratio in 2023. The registration date is June 19th.
Beijing Tiantan Biological Products Corporation (600161.SH) has announced that the company will implement annual equity distribution for the year 2023, with a dividend of per share...
Huaxin Securities: Both the supply and demand sides of blood products continue to improve, and the scale effect of leading companies gradually emerges.
According to the research reports released by Huaxin Securities, with the support and attention of domestic policies, the planning of new plasma stations such as the "14th Five-Year Plan" will gradually be implemented, and the construction of plasma stations will accelerate. China's plasma collection scale will continue to increase. In 2023, the plasma collection volume will exceed 12079 tons, an increase of more than 18.6% compared with 2022. Blood products belong to essential pharmaceuticals, and the entire industry is a licensed business, which determines its natural high policy barrier characteristics. The scale of plasma collection, the comprehensive utilization rate of blood plasma, and the profit-making ability of blood plasma are the core factors. The scale of plasma collection directly determines the scale of the enterprise. The number of existing varieties and research products are used to determine the comprehensive utilization rate and profit-making ability of blood plasma.
Tiantan Biology (600161.SH): Affiliated companies obtained approval notices for drug supplementation applications and passed drug GMP compliance checks
Gelonghui, April 10 | Tiantan Biology (600161.SH) announced that Chengdu Rongsheng Pharmaceutical Co., Ltd. recently received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration. The “human fibrinogen” developed by Chengdu Rongsheng complies with the relevant requirements for drug registration. At the same time, Chengdu Rongsheng's relevant production site has passed the drug GMP compliance inspection and obtained the “Drug GMP Site Inspection Results Notice” issued by the Sichuan Drug Administration. Chengdu Rongsheng has obtained the “Human Fibrinogen [Specification: 0.5g (25m1) /bottle]” drug supplement application approval
No Data